Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis

Canadian Respiratory Journal

Volumn 22, Issue 5, 2015, Pages 263-265

  Gibbons, E ^a   Promislow, S ^a   Davies, R A ^a   Chandy, G ^a   Stewart, D J ^a   Contreras Dominguez, V ^a   Pugliese, C ^a   Dunne, R ^a   Mielniczuk, L M ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Diagnosis; Interferon treatment; Multiple sclerosis; Pulmonary artery hypertension

Indexed keywords

AMBRISENTAN; BETA INTERFERON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLATIRAMER; TADALAFIL; WARFARIN; ANTIHYPERTENSIVE AGENT; IMMUNOLOGIC FACTOR; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE;

ADULT; BLOOD PRESSURE MEASUREMENT; BORDERLINE HYPERTENSION; CASE REPORT; CENTRAL VENOUS PRESSURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART CATHETERIZATION; HEART INDEX; HEART OUTPUT; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART SOUND; HEART VENTRICLE FUNCTION; HEART VENTRICLE OVERLOAD; HOSPITAL ADMISSION; HUMAN; HYPOVOLEMIA; HYPOXEMIA; HYPOXIA; LUNG ARTERY PRESSURE; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MAINTENANCE THERAPY; MEDICAL HISTORY; MIDDLE AGED; MONOTHERAPY; MULTIPLE SCLEROSIS; OXYGEN SATURATION; PATENT FORAMEN OVALE; PATIENT PREFERENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETURN TO WORK; RIGHT VENTRICULAR SYSTOLIC DYSFUNCTION; STANDING; SYSTOLIC DYSFUNCTION; THORAX PAIN; TREATMENT DURATION; TRICUSPID VALVE REGURGITATION; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPLICATION; HYPERTENSION, PULMONARY;

ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS; PHENYLPROPIONATES; PYRIDAZINES; TADALAFIL;

EID: 84944039269     PISSN: 11982241     EISSN: 19167245     Source Type: Journal    
DOI: 10.1155/2015/181535     Document Type: Conference Paper

References (11)

1. Simonneau G, Gatzoulis M, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-41.
2. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharm Ther 2012;135:44-53.
3. Dhillon S, Kaker A, Dosanjh A, Japra D, Van Thiel DH. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 2010;55:1785-90.
4. Ledinek AH, Jazbec SS, Drinovec I, Rot U. Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: A case report. Mult Scler 2009;15:885-6.
5. Caravita S, Secchi MB, Wu SC, Pierini S, Paggi A. Sildenafil therapy for interferon-b-1a-induced pulmonary arterial hypertension: A case report. Cardiology 2011;120:187-9.
6. Hanoka M, Kubo K, Hayano T, et al. Interferon alpha elevates pulmonary blood pressure in sheep-the role of thromboxane cascase. Eur J Pharmacol 1999;370:145-51.
7. Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM. Endothelin-1 is induced by cytokines in huam vascular smooth muscle cells; evidence for intracellular endothelin converting enzyme. Mol Pharma 1999;64:923-31.
8. Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: Relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Resp Cell Mol Biol 2001;25:104-10.
9. Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62:D60-72.
10. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. J Heart Lung Transplant 2012;31:150-8.
11. Galie N, et al. AMBITION: A randomised, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). Eur Respir J 2014;44(Suppl)58:Abstract 2916.